Metabolism-Clinical and Experimental

Article	Citations
A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on	410
Obesity in patients with COVID-19: a systematic review and meta-analysis	340
Insulin resistance, cardiovascular stiffening and cardiovascular disease	321
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses	308
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences	201
MAFLD and risk of CKD	200
Role of the gut microbiota in type 2 diabetes and related diseases	187
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease	150
The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis	143
Metformin: Is it a drug for all reasons and diseases?	134
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk	128
Insulin resistance and insulin sensitizing agents	120
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes	117
Insulin: The master regulator of glucose metabolism	117
Visceral fat is associated to the severity of COVID-19	105
The serum metabolome of COVID-19 patients is distinctive and predictive	102
Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis	99
Heart failure in diabetes	98
Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy	91
FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis	88
The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis	78
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression	77
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?	73
Mediterranean diet as a nutritional approach for COVID-19	69
Diabetes and COVID-19: The past, the present, and the future	66

Factors affecting weight loss variability in obesity	65
Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence	64
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies	64
Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data	63
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes	63
Mitochondrial quality control mechanisms as molecular targets in diabetic heart	62
Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study	62
Mitochondrial dysfunction in diabetic tubulopathy	61
The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000–2019	61
Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming	59
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage	58
FOS/GOS attenuates high-fat diet induced bone loss via reversing microbiota dysbiosis, high intestinal permeability and systemic inflammation in mice	57
Pharmacotherapy of type 2 diabetes: An update and future directions	57
UCP1-dependent and UCP1-independent metabolic changes induced by acute cold exposure in brown adipose tissue of mice	56
Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester	55
Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway	54
Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy	54
Functions of amyloid precursor protein in metabolic diseases	54
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis	53
METTL3 is required for maintaining β-cell function	51
Sarcopenia, osteoporosis and frailty	50
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease	50
Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus	50
Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers	49
Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts	49
Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name	48
Regulation of NAD+ metabolism in aging and disease	48
Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19	48
Lipids activate skeletal muscle mitochondrial fission and quality control networks to induce insulin resistance in humans	45
C C chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice	42
Beclin1 haploinsufficiency rescues low ambient temperature-induced cardiac remodeling and contractile dysfunction through inhibition of ferroptosis and mitochondrial injury	42
Advances in biological therapies for dyslipidemias and atherosclerosis	41
Machine learning and semi-targeted lipidomics identify distinct serum lipid signatures in hospitalized COVID-19-positive and COVID-19-negative patients	39
Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone	39
Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study	39
Deacetylation of Caveolin-1 by Sirt6 induces autophagy and retards high glucose-stimulated LDL transcytosis and atherosclerosis formation	39
CT-derived abdominal adiposity: Distributions and better predictive ability than BMI in a nationwide study of 59,429 adults in China	37
The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study	37
SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1	37
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists	36
Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study	36
Basal weekly insulins: the way of the future!	36
Exosomes: Advances, development and potential therapeutic strategies in diabetic nephropathy	35
Sarcopenia in youth	35
Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: Population-based, prospective cohort study	33
Exercise timing influences multi-tissue metabolome and skeletal muscle proteome profiles in type 2 diabetic patients – A randomized crossover trial	33
Type VI collagen and its cleavage product, endotrophin, cooperatively regulate the adipogenic and lipolytic capacity of adipocytes	33
Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure	33
Management of diabetic neuropathy	32
CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status	32

Current and investigational medications for the treatment of sarcopenia	32
Epigenetic modifications in diabetes	32
Bone morphogenetic proteins (BMPs) in the central regulation of energy balance and adult neural plasticity	31
Diabetes and metabolic dysfunction-associated fatty liver disease	31
Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice	31
Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk	31
Dietary carbohydrate intake and new-onset diabetes: A nationwide cohort study in China	30
TBC1D15-Drp1 interaction-mediated mitochondrial homeostasis confers cardioprotection against myocardial ischemia/reperfusion injury	30
Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease	30
Body fatness associations with cancer: evidence from recent epidemiological studies and future directions	29
Sarcopenic obesity: emerging mechanisms and therapeutic potential	29
Preparing for the NASH epidemic: A call to action	29
SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study	28
Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors	28
Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes	28
Glucose transporter 3 in neuronal glucose metabolism: Health and diseases	28
Commentary: COVID-19 and obesity pandemics converge into a syndemic requiring urgent and multidisciplinary action	27
Commentary. Eliminating vitamin D deficiency during the COVID-19 pandemic: A call to action	27
Risk of incident diabetes after COVID-19 infection: A systematic review and meta-analysis	27
Adherence to the EAT-Lancet diet, genetic susceptibility, and risk of type 2 diabetes in Swedish adults	27
Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice	27
Excess body weight is an independent risk factor for severe forms of COVID-19	27
ApoCIII: A multifaceted protein in cardiometabolic disease	27
cAMP-response element binding protein mediates podocyte injury in diabetic nephropathy by targeting lncRNA DLX6-AS1	27
TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury	27
Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis	27
From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need	26
The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis	26
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges	26
The IL-8-CXCR1/2 axis contributes to diabetic kidney disease	26
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease	25
SGLT-2 inhibitors as cardio-renal protective agents	25
Artificial intelligence and diabetes technology: A review	25
Vascular smooth muscle cell c-Fos is critical for foam cell formation and atherosclerosis	25
Hyperglycemia-reduced NAD+ biosynthesis impairs corneal epithelial wound healing in diabetic mice	24
Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19	24
Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study	24
Roles of malate and aspartate in gluconeogenesis in various physiological and pathological states	24
Higd1a facilitates exercise-mediated alleviation of fatty liver in diet-induced obese mice	24
Metformin coordinates with mesenchymal cells to promote VEGF-mediated angiogenesis in diabetic wound healing through Akt/mTOR activation	23
Adiponectin promotes repair of renal tubular epithelial cells by regulating mitochondrial biogenesis and function	23
Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes	23
Synergistic effects of fructose and glucose on lipoprotein risk factors for cardiovascular disease in young adults	23
GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease	23
Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes	22
Incretin-based therapies in 2021 – Current status and perspectives for the future	22
Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease	22
Circulating α-klotho regulates metabolism via distinct central and peripheral mechanisms	22
A healthy lifestyle, Life's Essential 8 scores and new-onset severe NAFLD: A prospective analysis in UK Biobank	22
Metabolic impact of weight loss induced reduction of adipose ACE-2 – Potential implication in COVID-19 infections?	22
Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart	22
Maternal high-fat high-sucrose diet and gestational exercise modulate hepatic fat accumulation and liver mitochondrial respiratory capacity in mothers and male offspring	22
Tricarboxylic acid cycle related-metabolites and risk of atrial fibrillation and heart failure	22
Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases	22
The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials	22
The MafA-target gene PPP1R1A regulates GLP1R-mediated amplification of glucose-stimulated insulin secretion in β-cells	22
Adipose tissue adipokines and lipokines: Functions and regulatory mechanism in skeletal muscle development and homeostasis	21
Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?	21
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity	21
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD	21
High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study	21
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study	21
Editorial: Obesity, metabolic phenotypes and COVID-19	21
Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist	21
Identification of a novel leptin receptor (LEPR) variant and proof of functional relevance directing treatment decisions in patients with morbid obesity	21
Loss of postprandial insulin clearance control by Insulin-degrading enzyme drives dysmetabolism traits	21
AMP-activated protein kinase (AMPK) signaling in GnRH neurons links energy status and reproduction	20
Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea	20
Systematic review with meta-analysis of diagnostic test accuracy for COVID-19 by mass spectrometry	20
Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis	20
Upstream and downstream regulators of Klotho expression in chronic kidney disease	20
Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF-κB pathway	20
Beyond mitochondria: Alternative energy-producing pathways from all strata of life	20
Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation	20
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States	20
AMP deamination is sufficient to replicate an atrophy-like metabolic phenotype in skeletal muscle	19
A requirement for PAK1 to support mitochondrial function and maintain cellular redox balance via electron transport chain proteins to prevent β-cell apoptosis	19
Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability	19
Association of class number, cumulative exposure, and earlier initiation of antibiotics during the first two-years of life with subsequent childhood obesity	19
Adiponectin's mechanisms in high-density lipoprotein biogenesis and cholesterol efflux	19

Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe di	19
Effects of aerobic exercise on fibroblast growth factor 21 in overweight and obesity. A systematic review	19
Histone methyltransferases G9a mediated lipid-induced M1 macrophage polarization through negatively regulating CD36	19
Downregulation of NK cell activities in Apolipoprotein C-III-induced hyperlipidemia resulting from lipid-induced metabolic reprogramming and crosstalk with lipid-laden dendritic cells	18
Inhibition of S100A8/A9 ameliorates renal interstitial fibrosis in diabetic nephropathy	18
Effects of bariatric surgery on lipid-lipoprotein profile	18
Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)	18
miRNA-22 deletion limits white adipose expansion and activates brown fat to attenuate high-fat diet-induced fat mass accumulation	18
Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH	18
Mendelian randomization study of obesity and type 2 diabetes in hospitalized COVID-19 patients	18
Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy	18
Diet for the prevention and management of sarcopenia	18
Diabetic ketoacidosis in pediatric patients with type 1- and type 2 diabetes during the COVID-19 pandemic	18
Recent advances in closed-loop insulin delivery	18
Reconstituted HDL-apoE3 promotes endothelial cell migration through ID1 and its downstream kinases ERK1/2, AKT and p38 MAPK	17
Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy?	17
PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study	17
Brown adipose tissue transplantation ameliorates diabetic nephropathy through the miR-30b pathway by targeting Runx1	17
Dynamic assessment of insulin secretion and insulin resistance in Asians with prediabetes	17
SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis	17
FGF21 and Chronic Kidney Disease	17
REEP6 knockout leads to defective β-adrenergic signaling in adipocytes and promotes obesity-related metabolic dysfunction.	17
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial	17
Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort	17
TNFα-induced NLRP3 inflammasome mediates adipocyte dysfunction and activates macrophages through adipocyte-derived lipocalin 2	16
Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis	16
MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice	16
Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study	16
Urinary GC–MS steroid metabotyping in treated children with congenital adrenal hyperplasia.	16
The β-cell glucose toxicity hypothesis: Attractive but difficult to prove	16
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives	16
Targeting FABP4 in elderly mice rejuvenates liver metabolism and ameliorates aging-associated metabolic disorders	16
Noradrenergic fibers are associated with beta-cell dedifferentiation and impaired beta-cell function in humans	16
Downregulation of the m6A reader protein YTHDC1 leads to islet β-cell failure and diabetes	16
Defining and diagnosing sarcopenia: Is the glass now half full?	16
Taurine treatment reverses protein malnutrition-induced endothelial dysfunction of the pancreatic vasculature: The role of hydrogen sulfide	16
The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling	16
Metabolically unhealthy individuals, either with obesity or not, have a higher risk of critical coronavirus disease 2019 outcomes than metabolically healthy individuals without obesity	16
Lipid-induced glucose intolerance is driven by impaired glucose kinetics and insulin metabolism in healthy individuals	16
Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters	16
Interplay of skeletal muscle and adipose tissue: sarcopenic obesity	16
Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings	15
Hepatic insulin receptor: new views on the mechanisms of liver disease	15
Inhibiting glycolysis rescues memory impairment in an intellectual disability Gdi1-null mouse	15
Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies	15
YY1 deficiency in β-cells leads to mitochondrial dysfunction and diabetes in mice	15
LPS-enriched small extracellular vesicles from metabolic syndrome patients trigger endothelial dysfunction by activation of TLR4	15
S100a16 deficiency prevents hepatic stellate cells activation and liver fibrosis via inhibiting CXCR4 expression	15
Laminins in metabolic tissues	14
AGEs exacerbates coronary microvascular dysfunction in NoCAD by activating endoplasmic reticulum stress-mediated PERK signaling pathway	14
Insulin discovery: A pivotal point in medical history	14
Pathophysiology of sarcopenia: Genetic factors and their interplay with environmental factors	14
Glutamine metabolism: from proliferating cells to cardiomyocytes	14
Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K/Akt signaling pathway in diabetic mice	14
Fyn deficiency inhibits oxidative stress by decreasing c-Cbl-mediated ubiquitination of Sirt1 to attenuate diabetic renal fibrosis	14
The role of the CCL25-CCR9 axis in beta-cell function: potential for therapeutic intervention in type 2 diabetes	14
Regulation of pericyte metabolic reprogramming restricts the AKI to CKD transition	14
The mitochondrial NAD+ transporter SLC25A51 is a fasting-induced gene affecting SIRT3 functions	14
Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity	14
The chronic effect of cortisol on orchestrating cerebral blood flow and brain functional connectivity: evidence from Cushing's disease	14
The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes	14
Direct impact of gonadotropins on glucose uptake and storage in preovulatory granulosa cells: Implications in the pathogenesis of polycystic ovary syndrome	13
Prandial hepatic glucose production during hypoglycemia is altered after gastric bypass surgery and sleeve gastrectomy	13
The nutrient sensing pathways FoxO1/3 and mTOR in the heart are coordinately regulated by central leptin through PPARβ/δ. Implications in cardiac remodeling	13
Effect of long-term testosterone therapy on molecular regulators of skeletal muscle mass and fibre-type distribution in aging men with subnormal testosterone	13
Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes	13
Fibroblast growth factor 21: A “rheostat” for metabolic regulation?	13
The role of ROS in tumor infiltrating immune cells and cancer immunotherapy	13
ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease	13
Atypical antipsychotic drugs deregulate the cholesterol metabolism of macrophage-foam cells by activating NOX-ROS-PPARγ-CD36 signaling pathway	13
Four-and-a-half LIM domain protein 2 (FHL2) deficiency protects mice from diet-induced obesity and high FHL2 expression marks human obesity	13
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease	13
Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism	13
A longitudinal analysis of arterial stiffness and wave reflection in preeclampsia: Identification of changepoints	13
Reduced brown adipose tissue activity during cold exposure is a metabolic feature of the human thrifty phenotype	13
Syntaxin17 contributes to obesity cardiomyopathy through promoting mitochondrial Ca2+ overload in a Parkin-MCUb-dependent manner	13
Epigenetic modification in alcohol use disorder and alcoholic cardiomyopathy: From pathophysiology to therapeutic opportunities	13
Interesterified palm oil impairs glucose homeostasis and induces deleterious effects in liver of Swiss mice	13
Prolyl isomerase Pin1 interacts with adipose triglyceride lipase and negatively controls both its expression and lipolysis	12
Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effec	12
Early benefits of bariatric surgery on subclinical cardiac function: Contribution of visceral fat mobilization	12
Exercise alleviates neovascular age-related macular degeneration by inhibiting AIM2 inflammasome in myeloid cells	12
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis	12
Aerobic exercise for eight weeks provides protective effects towards liver and cardiometabolic health and adipose tissue remodeling under metabolic stress for one week: A study in mice	12
Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction	12
Circulating lipoprotein(a) levels and health outcomes: Phenome-wide Mendelian randomization and disease-trajectory analyses	12
LKB1 up-regulation inhibits hypothalamic inflammation and attenuates diet-induced obesity in mice	12
FAM3A maintains metabolic homeostasis by interacting with F1-ATP synthase to regulate the activity and assembly of ATP synthase	12
Insulin regulates arginine-stimulated insulin secretion in humans	12
Kdm6a deficiency in microglia/macrophages epigenetically silences Lcn2 expression and reduces photoreceptor dysfunction in diabetic retinopathy	12
VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis	12
n-3 PUFA dietary lipid replacement normalizes muscle mitochondrial function and oxidative stress through enhanced tissue mitophagy and protects from muscle wasting in experimental kidney disease	12
Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: Pathophysiology, molecular biology, and potential clinical implications	12
Diabetes in pregnancy 100 years after the discovery of insulin: Hot topics and open questions to be addressed in the coming years	12
Increased plasma fatty acid clearance, not fatty acid concentration, is associated with muscle insulin resistance in people with obesity	12